Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Samuel Rabkin, Ph.D.

Co-Author

This page shows the publications co-authored by Samuel Rabkin and Robert Martuza.
Connection Strength

7.685
  1. In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV. Viruses. 2021 Aug 31; 13(9).
    View in: PubMed
    Score: 0.245
  2. Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma. J Immunother Cancer. 2020 05; 8(1).
    View in: PubMed
    Score: 0.224
  3. Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma. Nat Commun. 2019 07 02; 10(1):2910.
    View in: PubMed
    Score: 0.211
  4. Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells. Mol Ther Oncolytics. 2019 Jun 28; 13:58-66.
    View in: PubMed
    Score: 0.207
  5. Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of ?34.5 in Glioblastoma Stem-Like Cells. J Virol. 2018 08 01; 92(15).
    View in: PubMed
    Score: 0.198
  6. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. Immunotherapy. 2018 07; 10(9):779-786.
    View in: PubMed
    Score: 0.197
  7. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models. Clin Cancer Res. 2018 07 15; 24(14):3409-3422.
    View in: PubMed
    Score: 0.194
  8. Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade. Oncoscience. 2017 Jul; 4(7-8):67-69.
    View in: PubMed
    Score: 0.187
  9. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. Cancer Cell. 2017 08 14; 32(2):253-267.e5.
    View in: PubMed
    Score: 0.185
  10. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma. J Natl Cancer Inst. 2017 03 01; 109(3):1-13.
    View in: PubMed
    Score: 0.180
  11. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol. 2014 Aug; 16(8):1057-66.
    View in: PubMed
    Score: 0.145
  12. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):12006-11.
    View in: PubMed
    Score: 0.139
  13. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia. 2013 Jun; 15(6):591-9.
    View in: PubMed
    Score: 0.139
  14. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene Ther. 2013 Jan; 20(1):17-24.
    View in: PubMed
    Score: 0.133
  15. Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med. 2012 Apr; 1(4):322-32.
    View in: PubMed
    Score: 0.128
  16. Effect of ?34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol. 2012 Apr; 86(8):4420-31.
    View in: PubMed
    Score: 0.127
  17. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst. 2012 Jan 04; 104(1):42-55.
    View in: PubMed
    Score: 0.125
  18. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 2012 Feb; 14(2):132-44.
    View in: PubMed
    Score: 0.124
  19. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res. 2011 Dec 01; 17(23):7383-93.
    View in: PubMed
    Score: 0.124
  20. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther. 2012 Jan; 20(1):37-45.
    View in: PubMed
    Score: 0.123
  21. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res. 2011 Jun 01; 17(11):3686-96.
    View in: PubMed
    Score: 0.120
  22. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res. 2010 May 15; 70(10):3890-5.
    View in: PubMed
    Score: 0.112
  23. Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther. 2010 Jun; 17(6):805-10.
    View in: PubMed
    Score: 0.111
  24. Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther. 2009 Dec; 16(12):1477-82.
    View in: PubMed
    Score: 0.109
  25. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009 Apr 15; 69(8):3472-81.
    View in: PubMed
    Score: 0.104
  26. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther. 2009 Jul; 16(7):551-60.
    View in: PubMed
    Score: 0.103
  27. Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol Ther. 2009 Jan; 17(1):51-6.
    View in: PubMed
    Score: 0.101
  28. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther. 2008 Jun; 16(6):1041-7.
    View in: PubMed
    Score: 0.097
  29. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clin Cancer Res. 2007 Oct 01; 13(19):5897-902.
    View in: PubMed
    Score: 0.094
  30. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res. 2007 Oct 01; 67(19):9371-9.
    View in: PubMed
    Score: 0.094
  31. Oncolytic herpes simplex virus therapy for peripheral nerve tumors. Neurosurg Focus. 2007 Jun 15; 22(6):E4.
    View in: PubMed
    Score: 0.092
  32. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res. 2007 Jan 15; 67(2):440-4.
    View in: PubMed
    Score: 0.089
  33. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res. 2006 Nov 15; 12(22):6791-9.
    View in: PubMed
    Score: 0.088
  34. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res. 2006 Oct 15; 66(20):10127-35.
    View in: PubMed
    Score: 0.088
  35. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol. 2006 Sep 22; 6:40.
    View in: PubMed
    Score: 0.087
  36. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res. 2006 May 01; 12(9):2919-27.
    View in: PubMed
    Score: 0.085
  37. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther. 2006 Mar; 13(3):253-65.
    View in: PubMed
    Score: 0.084
  38. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst. 2006 Jan 04; 98(1):38-50.
    View in: PubMed
    Score: 0.083
  39. Oncolytic herpes simplex virus mutants exhibit enhanced replication in glioma cells evading temozolomide chemotherapy through deoxyribonucleic acid repair. Clin Neurosurg. 2006; 53:65-76.
    View in: PubMed
    Score: 0.083
  40. 840 Enhanced Replication of Oncolytic Herpes Simplex Virus in Glioma Cells that Evade Temozolomide Chemotherapy through DNA Repair. Neurosurgery. 2005 Aug 01; 57(2):408-409.
    View in: PubMed
    Score: 0.081
  41. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther. 2005 Apr; 12(8):647-54.
    View in: PubMed
    Score: 0.079
  42. Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer. Neoplasia. 2001 Sep-Oct; 3(5):451-6.
    View in: PubMed
    Score: 0.061
  43. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum Gene Ther. 2001 May 20; 12(8):999-1010.
    View in: PubMed
    Score: 0.060
  44. Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res. 2001 Apr 01; 61(7):3009-15.
    View in: PubMed
    Score: 0.060
  45. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther. 2001 Feb; 8(4):332-9.
    View in: PubMed
    Score: 0.059
  46. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. Cancer Res. 2001 Jan 01; 61(1):153-61.
    View in: PubMed
    Score: 0.059
  47. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. Acta Neuropathol Commun. 2020 12 11; 8(1):221.
    View in: PubMed
    Score: 0.058
  48. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther. 2000 Dec; 2(6):588-95.
    View in: PubMed
    Score: 0.058
  49. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma. Clin Cancer Res. 2021 02 01; 27(3):889-902.
    View in: PubMed
    Score: 0.058
  50. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther. 2000 Oct; 2(4):324-9.
    View in: PubMed
    Score: 0.058
  51. Clinical mutations in the L1 neural cell adhesion molecule affect cell-surface expression. J Neurosci. 2000 Aug 01; 20(15):5696-702.
    View in: PubMed
    Score: 0.057
  52. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther. 2000 Jun; 7(6):939-46.
    View in: PubMed
    Score: 0.056
  53. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000 May; 7(10):867-74.
    View in: PubMed
    Score: 0.056
  54. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol. 2000 Apr; 74(8):3832-41.
    View in: PubMed
    Score: 0.056
  55. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther. 1999 Nov 20; 10(17):2741-55.
    View in: PubMed
    Score: 0.054
  56. Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy. Hum Gene Ther. 1999 Nov 20; 10(17):2869-78.
    View in: PubMed
    Score: 0.054
  57. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 1999 Oct; 6(10):1751-8.
    View in: PubMed
    Score: 0.054
  58. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther. 1999 Sep 01; 10(13):2237-43.
    View in: PubMed
    Score: 0.053
  59. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol. 1999 Aug; 73(8):6319-26.
    View in: PubMed
    Score: 0.053
  60. A Monoclonal Antibody Against ß1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma. Target Oncol. 2019 08; 14(4):479-489.
    View in: PubMed
    Score: 0.053
  61. Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia. 1999 Jun; 1(2):162-9.
    View in: PubMed
    Score: 0.052
  62. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther. 1999 Apr; 6(4):564-72.
    View in: PubMed
    Score: 0.052
  63. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 1999 Feb 10; 10(3):385-93.
    View in: PubMed
    Score: 0.051
  64. Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy. Sci Rep. 2019 01 15; 9(1):139.
    View in: PubMed
    Score: 0.051
  65. Novel synthesis and release of GABA in cerebellar granule cell cultures after infection with defective herpes simplex virus vectors expressing glutamic acid decarboxylase. Brain Res Mol Brain Res. 1998 Oct 30; 61(1-2):121-35.
    View in: PubMed
    Score: 0.050
  66. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther. 1998 Oct 10; 9(15):2177-85.
    View in: PubMed
    Score: 0.050
  67. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol. 1998 May 01; 160(9):4457-64.
    View in: PubMed
    Score: 0.049
  68. Blockade of transforming growth factor-ß signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models. Int J Cancer. 2017 12 01; 141(11):2348-2358.
    View in: PubMed
    Score: 0.046
  69. Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol. 1997 Jul; 71(7):5124-32.
    View in: PubMed
    Score: 0.046
  70. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther. 1997 Jul-Aug; 4(4):222-8.
    View in: PubMed
    Score: 0.046
  71. Expression of L1 in primary astrocytes via a defective herpes simplex virus vector promotes neurite outgrowth and neural cell migration. Brain Res Mol Brain Res. 1996 Dec 31; 43(1-2):311-20.
    View in: PubMed
    Score: 0.044
  72. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro Oncol. 2016 09; 18(9):1278-87.
    View in: PubMed
    Score: 0.042
  73. Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma. Am J Cancer Res. 2016; 6(2):300-11.
    View in: PubMed
    Score: 0.042
  74. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 1995 Nov 01; 55(21):4752-6.
    View in: PubMed
    Score: 0.041
  75. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995 Sep; 1(9):938-43.
    View in: PubMed
    Score: 0.040
  76. Targeting Hypoxia-Inducible Factor 1a in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment. J Neuropathol Exp Neurol. 2015 Jul; 74(7):710-22.
    View in: PubMed
    Score: 0.040
  77. Inhibition of angiogenesis and growth of human non-malignant and malignant meningiomas by TNP-470. J Neurooncol. 1995; 23(1):23-9.
    View in: PubMed
    Score: 0.039
  78. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. J Neurooncol. 2015 Jan; 121(1):91-100.
    View in: PubMed
    Score: 0.038
  79. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994 Aug 01; 54(15):3963-6.
    View in: PubMed
    Score: 0.038
  80. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 2014 Apr 24; 157(3):580-94.
    View in: PubMed
    Score: 0.037
  81. CNS tumor therapy by attenuated herpes simplex viruses. Gene Ther. 1994; 1 Suppl 1:S78.
    View in: PubMed
    Score: 0.036
  82. Defective herpes simplex virus vectors for the study of promoter and gene function in the CNS. Gene Ther. 1994; 1 Suppl 1:S79.
    View in: PubMed
    Score: 0.036
  83. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep. 2013 May 30; 3(5):1567-79.
    View in: PubMed
    Score: 0.035
  84. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery. 2012 Sep; 71(3):741-8; discussion 748.
    View in: PubMed
    Score: 0.033
  85. Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors. Mol Ther. 2013 Jan; 21(1):68-77.
    View in: PubMed
    Score: 0.033
  86. Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging. Clin Cancer Res. 2011 Jul 01; 17(13):4484-93.
    View in: PubMed
    Score: 0.030
  87. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res. 2008 Dec 01; 14(23):7711-6.
    View in: PubMed
    Score: 0.025
  88. Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol. 2008 Dec; 173(6):1861-72.
    View in: PubMed
    Score: 0.025
  89. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther. 2007 May; 14(5):460-7.
    View in: PubMed
    Score: 0.022
  90. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther. 2006 Dec; 14(6):789-97.
    View in: PubMed
    Score: 0.022
  91. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther. 2006 Jan; 17(1):20-30.
    View in: PubMed
    Score: 0.021
  92. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res. 2005 Nov 01; 11(21):7886-90.
    View in: PubMed
    Score: 0.020
  93. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):421-8.
    View in: PubMed
    Score: 0.019
  94. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001 May 22; 98(11):6396-401.
    View in: PubMed
    Score: 0.015
  95. Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model. Exp Neurol. 2001 May; 169(1):64-71.
    View in: PubMed
    Score: 0.015
  96. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol. 1996 Aug; 50(2):236-42.
    View in: PubMed
    Score: 0.011
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.